Wei Dong

Dr. Wei Dong


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2022 in Cancer Letters
Verified
Journal Article
Open access
XMXiangui Meng
Xiangui Meng
WXWen Xiao
Wen Xiao
JSJiayin Sun
Jiayin Sun
WLWeiquan Li
Weiquan Li
HYHongwei Yuan
Hongwei Yuan
WDWei Dong
Wei Dong
Bladder cancer (BCa), characterized by high invasion, metastasis, recurrence, and chemoresistance, is one of the most prevalent urologic malignant tumors. Recent studies have highlighted the potential impact of the circRNAs-protein complex in tumorigenesis. However, the mechanisms by which the circRNAs-protein complex regulates BCa metastasis and chemoresistance remain elusive. Herein, we identified an upregulated circRNA, circPTK2, which could regulate SETDB1 expression by analyzing the transcriptome by RNA-sequencing. Importantly, using circRNA pulldown assay and RNA-binding protein immunoprecipitation, we identified PABPC1 as a robust novel interacting protein of circPTK2. Mechanistically, circPTK2 could bind to PABPC1 and enhance its ability to stabilize SETDB1 mRNA, thereby specifically promoting SETDB1 expression and facilitating SETDB1-mediated epithelial-mesenchymal transition (EMT). Functionally, overexpression of the circPTK2-SETDB1 axis markedly promoted migration, invasion, and gemcitabine resistance in vitro and enhanced lymph node metastasis in vivo. Collectively, our findings clarified a hitherto unexplored mechanism of the circPTK2/PABPC1/SETDB1 axis in EMT-mediated tumor metastasis and gemcitabine resistance in BCa.

12 September 2022 in Biological Procedures Online
Verified
Journal Article
Open access
PDF file
XMXiangui Meng
Xiangui Meng
WLWeiquan Li
Weiquan Li
HYHongwei Yuan
Hongwei Yuan
WDWei Dong
Wei Dong
XWXiao Wen
Xiao Wen
XZXiaoping Zhang
Xiaoping Zhang
Background: Bladder cancer (BCa) is a fatal form of cancer worldwide associated with a poor prognosis. Identifying novel drivers of growth and metastasis hold therapeutic potential for the disease. Transport homeostasis between the endoplasmic reticulum and Golgi and the secretion of matrix metalloproteinases (MMPs) mediated by Golgi have been reported to be closely associated with tumor progression. However, to date, mechanistic studies remain limited. Results: Here, we identified KDELR2 as a potential risk factor with prognostic value in patients with BCa, especially those harbouring the KDELR2 amplification. In addition, we found that KDELR2 is a regulator of BCa cell proliferation and tumorigenicity based on bioinformatic analysis with functional studies. Mechanistically, we revealed that KDELR2 could regulate the expression of KIF20A, thus stimulating the expression of MMP2, MMP9 and MKI67. Functionally, the overexpression of KDELR2 and KIF20A markedly promoted proliferation, migration, and invasion in vitro and enhanced tumor growth in vivo, while knockdown of KDELR2 and KIF20A exerted the opposite effects. And the overexpression of KDELR2 also enhanced lymph node metastasis in vivo. Conclusions: Collectively, our findings clarified a hitherto unexplored mechanism of KDELR2-KIF20A axis in increasing Golgi-mediated secretion of MMPs to drive tumor progression in BCa.

23 January 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
XMXiangui Meng
Xiangui Meng
WLWeiquan Li
Weiquan Li
TYTiexi Yu
Tiexi Yu
FLFeiyi Lu
Feiyi Lu
CWCheng Wang
Cheng Wang
XZXiaoping Zhang
Xiaoping Zhang

1 January 2026 in Oncology Research
Verified
Journal Article
Open access
PDF file
ZBZiyou Bai
Ziyou Bai
XSXiaoyan Song
Xiaoyan Song
JSJiayin Sun
Jiayin Sun
XWXiao Wen
Xiao Wen
XMXiangui Meng
Xiangui Meng
WDWei Dong
Wei Dong
Bladder cancer (BC) is a prevalent malignancy characterized by a high recurrence rate and the necessity for long-term surveillance demands, creating a need for accurate yet practical tools for early detection and monitoring. While current standards including cystoscopy, urinary cytology, and imaging remain indispensable, their clinical utility is constrained by invasiveness, suboptimal sensitivity for selected lesions or low-grade lesions, inter-observer variability, and cumulative costs. Currently, biomarker research has expanded from single protein assays to multi-analyte strategies encompassing DNA, RNA, proteins, extracellular vesicle-associated cargo, and metabolomics signatures. This review synthesizes recent advances in diagnostic, surveillance, prognostic, and treatment-predictive biomarkers, with emphasis on assay principles, analytical platforms and reported performance where available. Furthermore, we delineate critical barriers to translation, including limited prospective multicenter validation, heterogeneous pre-analytical workflows, inconsistent thresholds, and the persistent trade-off between sensitivity and specificity in real-world benign urologic conditions. Ultimately, while emerging biomarkers and multi-omics panels hold transformative potential as non-invasive adjuncts in risk-adapted clinical pathways, their routine adoption is contingent upon rigorous clinical integration and standardized validation.

20 September 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LCLijia Chen
Lijia Chen
MZMingjie Zhang
Mingjie Zhang
MCMiao Chi
Miao Chi
ZYZehua Ye
Zehua Ye
BLBojun Li
Bojun Li
XZXiangjun Zhou
Xiangjun Zhou
Background/Objectives: Cisplatin-induced acute kidney injury (AKI) is a major adverse complication restricting cisplatin-based chemotherapy. Ferroptosis contributes substantially to proximal tubular epithelial injury during AKI. This work aimed to explore the renoprotective effect of echinacoside (ECH) and its underlying molecular mechanism against cisplatin-provoked AKI. Methods: Eight-week-old male C57BL/6 cisplatin-AKI mice models and HK-2 tubular epithelial cells were used for in vivo and in vitro experiments. Public single-cell transcriptome data and 4D-DIA proteomics were applied to screen key ferroptosis-associated molecules. Functional validation, Western blotting, and molecular docking simulations were performed to characterize the regulatory axis of ECH. Results: ECH ameliorated renal dysfunction, inflammation, and tubular damage in cisplatin-induced AKI. Omics analyses nominated Bap1 as a critical ferroptosis-related differential protein. ECH restored the Slc7a11/GPX4 pathway to restrain lipid peroxidation and mitochondrial ferroptotic damage. Molecular docking predicted a potential interaction between ECH and Bap1. ECH downregulated Bap1 protein expression, and Bap1 overexpression largely abrogated ECH-mediated anti-ferroptosis and renoprotective effects. Conclusions: ECH mitigates cisplatin-triggered AKI, which is associated with Bap1 downregulation, Slc7a11/GPX4 axis restoration, and ferroptosis suppression. The ECH-Bap1-ferroptosis regulatory relationship offers a candidate therapeutic target and natural agent for the preventive treatment of cisplatin-related nephrotoxicity.